Quetiapine (Seroquel) Should NOT Be Used for Insomnia
Quetiapine is not recommended for the treatment of insomnia and should be avoided in favor of evidence-based alternatives. Major clinical practice guidelines explicitly exclude quetiapine from recommended pharmacologic treatments for chronic insomnia, and the available evidence demonstrates concerning safety risks that outweigh any potential sleep benefits 1.
Guideline Recommendations Are Clear
The 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline comprehensively reviewed pharmacologic treatments for chronic insomnia and notably does not include quetiapine among its recommendations 1. The guideline provides specific recommendations for:
- FDA-approved hypnotics: eszopiclone, zolpidem, zaleplon, suvorexant (all WEAK recommendations)
- Other agents with evidence: doxepin, ramelteon, benzodiazepines like temazepam and triazolam
The guideline explicitly recommends against using trazodone (another commonly misused sedating antidepressant) for insomnia 1. The complete absence of quetiapine from these guidelines is telling—it was not evaluated because insufficient quality evidence exists to support its use.
The 2016 American College of Physicians guideline similarly found insufficient evidence for antidepressants in insomnia treatment 2.
FDA Labeling Does Not Support This Use
Quetiapine is FDA-approved only for schizophrenia and bipolar disorder—not insomnia 3. The FDA label warns of multiple serious risks relevant to insomnia use:
- Cognitive and motor impairment: Somnolence leads to falls, impaired judgment, and inability to operate vehicles safely
- Increased mortality in elderly patients with dementia-related psychosis (Black Box Warning)
- Metabolic effects: Weight gain, hyperglycemia, dyslipidemia
- Anticholinergic effects: Constipation (risk factor for intestinal obstruction), urinary retention
- Discontinuation syndrome: Ironically includes insomnia, nausea, vomiting upon cessation
- Hypotension and falls
- QT prolongation
- Hyperprolactinemia and potential tumor risk
Research Evidence Shows Harm Outweighs Benefit
Mortality and Serious Adverse Events
A 2025 retrospective cohort study of older adults (≥65 years) found that low-dose quetiapine for insomnia was associated with 4:
- 3.1-fold increased mortality risk compared to trazodone (HR 3.1,95% CI 1.2-8.1)
- 8.1-fold increased dementia risk compared to trazodone (HR 8.1,95% CI 4.1-15.8)
- 7.1-fold increased dementia risk compared to mirtazapine (HR 7.1,95% CI 3.5-14.4)
- 2.8-fold increased fall risk compared to trazodone (HR 2.8,95% CI 1.4-5.3)
Lack of Efficacy Evidence
A 2016 systematic review found only one small RCT (n=13) evaluating quetiapine for primary insomnia 5. After 2 weeks, quetiapine showed no statistically significant improvements in:
- Total sleep time (MD 52.68 min, 95% CI -27.27 to 132.6)
- Sleep latency reduction (MD 72.44 min, 95% CI -2.65 to 147.5)
- Sleep satisfaction (MD 6.16,95% CI -12.32 to 24.64)
The evidence was rated as very low quality, and the authors concluded that "atypical antipsychotics should be avoided in the first-line treatment of primary insomnia" 5.
Next-Day Impairment
A 2026 randomized controlled trial in patients with OSA and difficulty maintaining sleep found that while 50 mg quetiapine modestly improved sleep efficiency, it significantly impaired 6:
- Next-morning vigilance: Median reaction time increased from 336 to 382 ms (P=0.008)
- Driving simulator performance: Steering deviation increased from 72 to 96 cm (P<0.01)
This demonstrates clinically meaningful functional impairment that directly impacts quality of life and safety.
Metabolic Adverse Effects
A 2023 meta-analysis found quetiapine improved subjective sleep quality (SMD -0.57) but noted that adverse events and discontinuation due to adverse events were common 7. A 2012 review found retrospective cohort studies showed significant weight gain even at low doses (25-200 mg/day) 8.
Clinical Bottom Line
Use FDA-approved hypnotics or other guideline-recommended agents instead:
First-line pharmacologic options (per AASM guidelines):
- Eszopiclone 2-3 mg for sleep onset/maintenance
- Zolpidem 10 mg for sleep onset/maintenance
- Suvorexant 10-20 mg for sleep maintenance
- Doxepin 3-6 mg for sleep maintenance
Consider cognitive behavioral therapy for insomnia (CBT-I) as the preferred non-pharmacologic approach
If quetiapine is already prescribed: Taper gradually to avoid discontinuation syndrome and transition to evidence-based alternatives
Key Pitfalls to Avoid
- Do not prescribe quetiapine for insomnia simply because it causes sedation—sedation does not equal therapeutic sleep improvement
- Particularly avoid in older adults given the dramatically increased risks of mortality, dementia, and falls 4
- Do not assume "low doses are safe"—metabolic effects, cognitive impairment, and serious adverse events occur even at 25-50 mg doses 8, 4
- Recognize that widespread off-label use does not equal evidence-based practice—quetiapine is one of the most commonly misprescribed medications for insomnia despite lack of supporting evidence 9, 10
The risk-benefit analysis clearly favors avoiding quetiapine for insomnia in favor of guideline-concordant alternatives with established efficacy and safety profiles.